New patent for Qol Medcl drug SUCRAID

Annual Drug Patent Expirations for SUCRAID
Annual Drug Patent Expirations for SUCRAID

Sucraid is a drug marketed by Qol Medcl
and is included in one NDA. It is available from one supplier.

The generic ingredient in SUCRAID is sacrosidase. One supplier is listed for this compound. Additional details are available on the sacrosidase profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most drug patents in Yugoslavia?

This chart shows the pharmaceutical companies with the most patents in Yugoslavia.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

For a global perspective, see the Drug companies with the greatest global patent coverage.

The companies with the greatest patent coverage in Yugoslavia are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Pernix Theraps drug SILENOR

Annual Drug Patent Expirations for SILENOR
Annual Drug Patent Expirations for SILENOR

Silenor is a drug marketed by Pernix Theraps Llc
and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twelve patent family members in four countries.

The generic ingredient in SILENOR is doxepin hydrochloride. One supplier is listed for this compound. Additional details are available on the doxepin hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Apotex Technologies drug PAXIL CR

Annual Drug Patent Expirations for PAXIL+CR
Annual Drug Patent Expirations for PAXIL+CR

Paxil Cr is a drug marketed by Apotex Technologies
and is included in one NDA. It is available from five suppliers. There are six patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in PAXIL CR is paroxetine hydrochloride. Five suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most drug patents in Singapore?

This chart shows the pharmaceutical companies with the most patents in Singapore.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

For a global perspective, see the Drug companies with the greatest global patent coverage.

The companies with the greatest patent coverage in Singapore are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Vanda Pharms drug HETLIOZ

Annual Drug Patent Expirations for HETLIOZ
Annual Drug Patent Expirations for HETLIOZ

Hetlioz is a drug marketed by Vanda Pharms Inc
and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.

This drug has sixty-seven patent family members in twenty-nine countries.

The generic ingredient in HETLIOZ is tasimelteon. One supplier is listed for this compound. Additional details are available on the tasimelteon profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Bausch And drug PROLENSA

Annual Drug Patent Expirations for PROLENSA
Annual Drug Patent Expirations for PROLENSA

Prolensa is a drug marketed by Bausch And Lomb
and is included in one NDA. It is available from one supplier. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in ten countries.

The generic ingredient in PROLENSA is bromfenac sodium. One supplier is listed for this compound. Additional details are available on the bromfenac sodium profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Pernix Ireland drug ZOHYDRO ER

Annual Drug Patent Expirations for ZOHYDRO+ER
Annual Drug Patent Expirations for ZOHYDRO+ER

Zohydro Er is a drug marketed by Pernix Ireland Pain
and is included in one NDA. It is available from two suppliers. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-one patent family members in thirty-two countries.

The generic ingredient in ZOHYDRO ER is hydrocodone bitartrate. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com